• Journal of the Korean hospital association
• /
• v.16 no.9 s.147
• /
• pp.22-25
• /
• 1987

• Korean Architects
• /
• s.529
• /
• pp.36-43
• /
• 2013

• Journal of the korean veterinary medical association
• /
• v.40 no.3
• /
• pp.241-249
• /
• 2004

• Water for future
• /
• v.39 no.6 s.155
• /
• pp.14-19
• /
• 2006

• Rubber Technology
• /
• v.21 no.2
• /
• pp.59-67
• /
• 2020

• Water for future
• /
• v.54 no.1
• /
• pp.81-86
• /
• 2021

• Journal of the Korean Society of Radiology
• /
• v.83 no.1
• /
• pp.1-2
• /
• 2022

• Journal of the Korean Society of Radiology
• /
• v.81 no.4
• /
• pp.755-755
• /
• 2020

• Journal of Veterinary Clinics
• /
• v.5 no.2
• /
• pp.87-94
• /
• 1988

To develop more reliable diagnostic measures for traumatic pericarditis in ruminant, fluctuations of serum total LDH activities and LDH isoenzymes fractions were investigated in artificially induced pericarditis of Korean native goats. Experimental group showed the tendency of increase serum LDH total activities. Effect of LDH isoenzymes on serum total LDH activities were high with decreasing order of LDH$_1$> LDH$_3$ > LDH$\sub$5/ > LDH$_2$ > LDH$_4$ and LDH$_1$ was the hightest among them. From these findings, increase of serum total LDH activities and LDH$_1$ fraction was thought to be important in traumatic pericarditis.

• The Korean Journal of Medicine
• /
• v.93 no.6
• /
• pp.501-508
• /
• 2018

Obesity is a chronic disorder that is a significant risk factor for diabetes, cardiovascular diseases, malignancy, and other chronic diseases. Lifestyle modifications form the basis of most treatments for obesity, but it has become clear that such modifications alone are not enough for many obese patients. When a behavioral approach is insufficient, pharmacological treatment may be recommended. In recent years, the US Food and Drug Administration (FDA) has withdrawn several therapeutic options for obesity due to their side effects, but has approved four novel anti-obesity agents. Until recently, orlistat was the only drug approved for the management of long-term obesity, but the US FDA approved the novel anti-obesity drugs lorcaserin and phentermine/topiramate in 2012, and naltrexone/bupropion and liraglutide in 2014. The present review discusses the different pharmacotherapeutic options for the treatment of obesity.